BTAI (BioXcel Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 08, 2026)


BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $0.81
GF Value $0.67
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Tariff Resilience Score?

BioXcel Therapeutics BTAI -22.87% 8 Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,029 Drug Manufacturers companies, BioXcel Therapeutics ranks better than 97.08% on this metric.

BioXcel Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

BioXcel Therapeutics has BioXcel Therapeutics is less affected by tariffs due to its focus on pharmaceuticals, which often have exemptions. Its supply chain is global, but it has strategic partnerships to mitigate risks. Historical tariffs have had limited impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioXcel Therapeutics might have Highly Resilient.

BioXcel Therapeutics  (NAS:BTAI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioXcel Therapeutics Tariff Resilience Score Related Terms

BTAI vs IXHL, SCYX, INIS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Tariff Resilience Score falls into.


BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
BioXcel Therapeutics (BTAI) has a Tariff Resilience Score of 7 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioXcel Therapeutics ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is BioXcel Therapeutics' Tariff Resilience Score too high?
BioXcel Therapeutics' current Tariff Resilience Score is 7. Based on the distribution chart, BioXcel Therapeutics ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Tariff Resilience Score compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #30 out of 1029 companies for Tariff Resilience Score. This places BioXcel Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. BioXcel Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.81 — trading 20.4% above its estimated fair value. The current Tariff Resilience Score is 7. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $0.81 is trading 20.4% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Modestly Overvalued.

Key valuation signals for BTAI:

  • Tariff Resilience Score: 7
  • GF Value™: $0.67 vs. price of $0.81 (20.4% above fair value)
  • GF Score™: 8/100 with 5 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$0.67
GF Value